Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 11 Desmoid Tumors 8 Neoplasms 3 Triple Negative Breast Neoplasms 1 Sarcoma, Kaposi 1 Paraproteinemias 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neoplasms, Plasma Cell 1 Neoplasms by Histologic Type 1 Leukemia 1 Hematologic Diseases 1 HIV Infections 1 Granulosa cell tumor of the ovary 1 Corneal Diseases 1 Breast Neoplasms 1 Breast Cancer Metastatic 1 Blood Protein Disorders 1 Advanced Solid Tumors 1 AIDS-related Kaposi sarcoma 1

Interventions

Trastuzumab 625 Paclitaxel 576 Cyclophosphamide 555 Docetaxel 484 Capecitabine 401 Letrozole 376 Fulvestrant 326 Doxorubicin 294 Carboplatin 279 Tamoxifen 275 Anastrozole 243 exemestane 228 Radiotherapy 218 Epirubicin 211 Bevacizumab 196 palbociclib 189 pertuzumab 184 Vinorelbine 167 Lapatinib 167 Gemcitabine 166 pembrolizumab 162 Surveys and Questionnaires 138 Exercise 136 Magnetic Resonance Spectroscopy 123 Fluorouracil 119 Blood Specimen Collection 118 eribulin 117 Albumin-Bound Paclitaxel 117 Drug Therapy 111 130-nm albumin-bound paclitaxel 111

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Breast Neoplasms × nirogacestat × Clear all

NCT02338531 2016-04-29

RHEA

Jules Bordet Institute

Phase 2 Withdrawn

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡